In developed countries, humans are potentially exposed to a wide range of chemicals present in commonly used products. For the most part, no information exists about the extent of the human exposure to these chemicals, and the potential toxic effects of these compounds are largely unknown. Bisphenol A (2,2′-bis\[4-hydroxyphenyl\]propane; BPA) and alkylphenols (APs) are among these chemicals. BPA is used to manufacture polycarbonate plastic and epoxy resins, which are used in baby bottles, as protective coatings on food containers, and for composites and sealants in dentistry ([@b2-ehp0113-000391]; [@b13-ehp0113-000391]; [@b34-ehp0113-000391]). APs are used to make alkylphenol ethoxylates (APEs), widely used nonionic surfactants. APEs are applied as emulsifying, wetting, dispersing, or stabilizing agents in numerous industrial, agricultural, and domestic consumer products including detergents and pesticide formulations ([@b27-ehp0113-000391]; [@b45-ehp0113-000391]). 4-Nonylphenol (NP) is one of the most widely used and studied APs \[[@b5-ehp0113-000391]; [@b39-ehp0113-000391]\]. BPA and NP can be released into the environment during the manufacturing process and by leaching from the final products ([@b8-ehp0113-000391]; [@b24-ehp0113-000391]; [@b36-ehp0113-000391]). Because of the widespread use of BPA and NP, the potential for human exposure is high.

Toxicologic studies of laboratory animals suggest that exposure to BPA and NP is associated with morphologic, functional, and behavioral anomalies related to reproduction. NP is estrogenic *in vitro* and *in vivo* ([@b21-ehp0113-000391]), interferes with the estrous cycle and pubertal onset in rats ([@b18-ehp0113-000391]; [@b22-ehp0113-000391]), and shows aquatic toxicity at low (micrograms per liter) concentrations ([@b11-ehp0113-000391]; [@b45-ehp0113-000391]). Exposure of rodent fetuses to low BPA doses of 20--400 μg/kg/day produces postnatal estrogenic effects, including reduced daily sperm production and increased prostate gland weight in males, alteration in the development and tissue organization of the mammary gland, disruption of sexual differentiation in the brain, long-term deleterious effects in the vagina, and accelerated growth and puberty in females ([@b12-ehp0113-000391]; [@b19-ehp0113-000391]; [@b25-ehp0113-000391]; [@b29-ehp0113-000391]; [@b35-ehp0113-000391]; [@b41-ehp0113-000391]; [@b42-ehp0113-000391]; [@b43-ehp0113-000391]). In mice treated with BPA at oral doses comparable with environmental exposure levels (20--100 μg/kg body weight/day), BPA appears to be a potent disruptor of meiosis, the cell division process that creates sperm or eggs, leading to aneuploidy ([@b14-ehp0113-000391]). Aneuploidy (an error in cell division) during meiosis is thought to be the most common known cause of mental retardation as well as being the leading genetic cause of pregnancy loss in humans ([@b10-ehp0113-000391]).

Data on human exposure to NP are scarce ([@b15-ehp0113-000391]; [@b17-ehp0113-000391]). NP was measured in the urine samples of 10 healthy volunteers using column-switching liquid chromatography/mass spectrometry ([@b15-ehp0113-000391]). NP was detected at concentrations higher than the limit of detection (LOD; 0.3 ng/mL) in one sample. Recently, NP was measured in five urine and three plasma samples from eight adult volunteers by using stir-bar sorptive extraction-thermal desorption--gas chromatography/mass spectrometry (GC/MS) ([@b17-ehp0113-000391]). The NP concentrations in urine were below the LOD (0.2 ng/mL).

The urinary BPA levels in various populations in Southeast Asia have been reported ([@b1-ehp0113-000391]; [@b26-ehp0113-000391]; [@b31-ehp0113-000391]; [@b44-ehp0113-000391]). BPA was measured in morning spot urine samples from two different groups of university students in Japan in 1992 (*n* = 50, 92% male) and 1999 (*n* = 56, 87.5% male). Most BPA was found in the urine as the glucuronide conjugate. The median urinary BPA levels in 1992 were approximately 2.2-fold higher than in 1999 ([@b26-ehp0113-000391]). In another study, BPA glucuronide was detected in all of the urine samples collected from 48 female Japanese college students at concentrations ranging from 0.2 to 19.1 ng/mL, with a median level of 1.2 μg/L (0.77 μg/g creatinine) ([@b31-ehp0113-000391]). The largest BPA nonoccupational exposure assessment reported urinary levels of BPA in a group of 73 adult Koreans (53.4% female). The geometric mean (GM) concentration of BPA was 9.54 μg/L (8.91 μg/g creatinine) ([@b44-ehp0113-000391]). A recent study in Japan reported a median daily urinary excretion of BPA of 1.2 μg/day and a maximum daily intake of BPA per body weight to be 0.23 μg/kg/day based on the measurement of BPA in 24-hr urine samples collected from 36 men ([@b1-ehp0113-000391]). This estimated maximum daily intake was lower than the temporary tolerable daily intake (10 μg/kg) set by the European Commission's Scientific Committee in Food in 2002 ([@b1-ehp0113-000391]; [@b6-ehp0113-000391]).

Occupational exposure to BPA has been assessed in a cross-sectional study involving 84 male workers in plastic plants in Japan ([@b9-ehp0113-000391]). Forty-two of the workers used bisphenol A diglycidyl ether (BADGE) and mixed organic solvents for spraying epoxy resin hardening agents, whereas the other 42 workers did not use BADGE. The median concentrations of urinary BPA were higher (*p* = 0.002) in the sprayers (1.06 μmol/mol creatinine) than in the nonexposed workers (0.52 μmol/mol creatinine). Similarly, the concentrations of urinary metabolites of the organic solvents used were significantly higher in the sprayers than in the nonexposed workers. In contrast, the median plasma concentrations of follicle-stimulating hormone (FSH) were lower (although within the normal range) in the sprayers than in the nonexposed workers (*p* = 0.022). The levels of FSH were slightly negatively correlated with those of BPA (correlation coefficient, −0.2, *p* = 0.071) but not with the metabolites of the organic solvents. On the basis of these results, the authors postulated that BPA may disrupt the secretion of gonadotropic hormones in men, although they also acknowledged that the clinical significance of these findings is still unclear and should be further investigated ([@b9-ehp0113-000391]).

Although no clear association has been established between human exposure to BPA or NP and adverse health effects, studies to investigate the prevalence of exposure to these environmental phenols are warranted because of their potential harmful effects. Here we report the levels of BPA and NP in urine from a demographically diverse sample of U.S. adults using a sensitive technique ([@b20-ehp0113-000391]) as a tool for assessing the internal dose of these compounds.

Materials and Methods
=====================

The urine samples analyzed for this study were selected from the Third National Health and Nutrition Examination Survey (NHANES III) callback cohort, a nonrepresentative subset of NHANES III composed of approximately 1,000 adults. The urine samples were all spot-urine samples, collected at different times throughout the day and were not necessarily first-morning voids. Creatinine adjustment was used to correct for urine dilution ([@b16-ehp0113-000391]).

BPA and 4-*n*-nonylphenol (nNP), the linear chain NP isomer, were measured using a method based on an automated solid-phase extraction (SPE) coupled to isotope dilution-GC/MS ([@b20-ehp0113-000391]). First, the urine samples were treated with β-glucuronidase to hydrolyze the glucuronide conjugates. Then, during the automated SPE process, BPA and nNP were both extracted from the deconjugated urine matrix and derivatized, using pentafluorobenzyl bromide, on commercial styrene-divinylbenzene copolymer-based SPE cartridges. After elution from the SPE column, the derivatized phenols in the SPE eluate were measured by isotope-dilution GC/MS. The limits of detection (LODs) for BPA and nNP in a 1-mL urine sample were 0.1 μg/L.

Quality control (QC) materials were analyzed along with the samples to assure the accuracy and reliability of the data. Low-concentration (QCL, 2--5 ng/mL) and high-concentration (QCH, 12--20 ng/mL) QC materials were prepared from a base urine pool---obtained from multiple anonymous donors as described previously ([@b20-ehp0113-000391])---dispensed in 5-mL aliquots and stored at −20°C. Each QC material was characterized by repeated measurements, spanned over at least 4 weeks, to define the mean concentrations and the 95% and 99% control limits of BPA and nNP. Each analytical run consisted of 40 (2 QCH, 2 QCL, 4 blanks, and 32 unknown) samples. The concentrations of the two QCH and the two QCL, averaged to obtain one measurement of QCH and QCL for each run, were evaluated using standard statistical probability rules.

The samples used for this study were stored securely at −70°C and may have been subject to repeated thaw/freeze cycles. Before analysis, the samples and QC materials were left to thaw overnight at 5°C. The concentrations of the analytes in the QCs remained essentially constant under these experimental conditions. Furthermore, QC materials reanalyzed after the initial characterization showed that BPA and nNP remained stable in the QC materials at −20°C for at least 1 year. Although the long-term stability of the analytes in the urine samples stored for \> 1 year is not known, the QC data suggest that the integrity of the specimens is likely maintained and that chemical degradation of the phenols was undetectable.

To estimate total sample size, we used a standard formula *n* = *t*^2^*p*(1 − *p*)/*d*^2^, where *n* is the estimated sample size, *t* is the critical value associated with the desired statistical confidence level, and *d* is the maximum allowable error above or below the estimate of the true proportion (*p*) of the target population with measurable levels of the analyte(s) of interest ([@b32-ehp0113-000391]). Using a confidence level of 99% (*t* = 2.6), *d* = 0.065, and a 50% percentage of the population with measurable BPA and nNP levels (*p* = 0.5), the estimated total sample size was 400. Participants in this study were 20--59 years of age, of both sexes, and urban and rural residents. An arbitrary cutoff of 100,000 inhabitants per county was used to distinguish rural from urban areas. Each sample, defined by age (\< 50 years or ≥50 years), residence (rural or urban), and sex (male or female), was categorized in eight subpopulation groups (e.g., \< 50-year-old rural female).

Because samples were obtained from the NHANES III callback cohort, a nonrepresentative subset of NHANES III samples, the summary statistics are not representative of the U.S. population but serve as reference ranges for the three population breakdowns specified above (i.e., persons \< 50 or ≥50 years of age; rural or urban residents; male or female). To improve the extent to which the results represent the U.S. population, we used sample weights. We developed our own weights for demographic groups, not for individual subjects. This approach is different from that used by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). The NCHS assigns a unique weight to each subject based on demographics, geographical data, and oversampling of certain population groups. Because we only had information on age group, sex, and residence (i.e., rural and urban), we could not assign weights to individual subjects, only to the demographic groups. We determined the weights by relating the sample sizes in each of the eight groups to the total numbers of persons in the U.S. population in the same groups defined by sex, residence, and age. From within these eight groups, we randomly selected 394 samples. The institutional review board of the NCHS approved the study.

We analyzed the weighted data using SAS software, version 8.2 (SAS Institute, Cary, NC). Because the base-10 logarithm of the concentrations (log-transformed concentrations) was less skewed than the nontransformed values, we used the log-transformed values in the analyses. We calculated GMs and distribution percentiles for both volume-based (micrograms per liter) and creatinine-corrected concentrations (micrograms per gram creatinine). The GMs were exponentiated results obtained from the means of the log-transformed concentrations. GMs were calculated when the frequency of detection of the analyte was \> 60%. We did not use weights to obtain GM or percentile estimates for the various demographic groups because each subject in a demographic group had the same weight.

For exploratory purposes only, we compared BPA and NP levels among subgroups (by age, sex, and place of residence) even though we did not design the study to assure adequate statistical power for this type of hypothesis testing (i.e., the sample size was determined to answer only the question about the percentage of population with measurable urinary BPA and/or NP levels). We used weighted analysis of covariance models to study the effects of residence, sex, age group, and urinary creatinine on the urinary log-transformed concentrations of BPA and NP. The analyses were performed using SAS Proc GENMOD (SAS Institute) to model the log-transformed concentrations (dependent variable) as a function of sex, residence, age group (categorical covariates), and urinary creatinine (continuous covariate used to adjust for urine dilution). The purpose of our model adjustment was not to apply an individual adjustment to BPA and NP concentrations, but rather to enable us to determine whether there are differences in average BPA or NP urinary levels between individuals in the same demographic groups (e.g., men vs. women) after accounting for the differences due to urinary dilution. By adjusting for creatinine, we obtained a comparison that was not influenced by differences in creatinine levels. We also considered all possible two-way interactions between covariates. Type 3 equivalent sums of squares from the model were used to form likelihood ratio tests of model effects and various tests of hypotheses. Statistical significance was set at *p* \< 0.05. We dealt with results \< LOD by using a multiple imputation method ([@b23-ehp0113-000391]) along with the SAS procedure PROC MIANALYZE, which summarizes parameter estimates and incorporates the resulting uncertainty associated with the multiple imputations used to obtain them.

Results
=======

The distributions of BPA and NP in 394 NHANES III callback cohort urine samples analyzed are shown in [Table 1](#t1-ehp0113-000391){ref-type="table"} and [Figure 1](#f1-ehp0113-000391){ref-type="fig"}, respectively. For NP, results were available for 371 samples. Ninety-five percent of the samples measured had detectable concentrations of BPA, suggesting that human exposure to BPA is widespread. NP was detected in 51% of the samples. The lower frequency of NP than BPA detection could be because nNP (the compound we measured) represents a small percentage of the NP present in the NP commercial mixtures, to relative differences in the used amounts of BPA and NP ethoxylates (the environmental precursors of NP), the degree of human exposure, the pathways and routes of exposure, pharmacokinetic factors (i.e., absorption, distribution, metabolism, and elimination), or a combination of all of the above.

Beginning with the initial BPA model described above, we arrived at a final model that included residence, creatinine, and residence-by-creatinine interaction ([Table 2](#t2-ehp0113-000391){ref-type="table"}). We calculated adjusted GM estimates of BPA for residence groups by using the mean values of the continuous covariate (i.e., creatinine). For BPA, the main effects for sex and age group were not statistically significant, and they were excluded from the final model. In contrast, the residence × creatinine term was statistically significant (*p* = 0.0249), suggesting that the estimated difference in BPA concentrations between urban and rural residents depended upon the urinary creatinine level, and that the relationship between urinary levels of BPA and creatinine is not the same for urban and rural residents. The adjusted GM of BPA for an urban resident (1.21 μg/L) was significantly lower (*p* = 0.0014) than that for a rural resident (1.56 μg/L). These values ([Table 2](#t2-ehp0113-000391){ref-type="table"}) compared well with the observed values ([Table 1](#t1-ehp0113-000391){ref-type="table"}). According to the model results, BPA levels for rural residents were expected to be 1.28 \[95% confidence interval (CI), 1.05--1.57\] times higher than those for urban residents assuming a urinary creatinine concentration in both groups of 12.63 mmol/L. Furthermore, on the basis of model results, every mmol/L increase in urinary creatinine levels was expected to be associated with a 5.8% (95% CI, 0.4--8.1%) increase in BPA levels for rural residents and a9.5% (95% CI, 7.2--11.9) increase for urban residents. These data suggest the possibility of variations in exposure to BPA on the basis of place of residence. However, the nature of these variations is not apparent (maybe due to differences in diet, lifestyle, or exposure to other chemicals) and is difficult to explain with the available demographic data.

For NP, no statistically significant interactions existed between any of the covariates considered, and none of the categorical main effects was statistically significant. Only urinary creatinine was statistically significant (*p* \< 0.0001). The slope (β) from the multivariate analysis of the regression of log~10~(NP) versus creatinine was 0.036. On the basis of model results, the NP GM concentration was \< LOD (0.1 μg/L), assuming all participants had an average urinary creatinine of 12.63 mmol/L. Furthermore, for every milli-mole per liter increase in urinary creatinine, NP concentration increased by 8.6% (95% CI, 5.6--11.7).

Because of the relatively large percentage of NP results \< LOD, we performed a logistic regression analysis to determine whether any of the covariates might be associated with an NP level large enough to be detected. The results of this analysis showed no evidence for an effect of the categorical covariates (i.e., sex, residence, age group) on the likelihood (i.e., probability) of a subject having a measurable NP concentration. For every mmol/L increase in creatinine concentrations, the likelihood of a measurable NP level increased by 9.1% (95% CI, 5.6--12.7), confirming that the likelihood of measurable NP levels is associated with increased urine concentration (using creatinine as an indicator of urine concentration) that also is directly related to increased NP concentrations. We found no significant correlation between the levels of urinary BPA and NP (data not shown). These findings suggest that, as expected, no common source of exposure exists for BPA and NP.

Discussion
==========

We measured BPA and NP in a group of 394 urine samples from the NHANES III callback cohort ([Table 1](#t1-ehp0113-000391){ref-type="table"}, [Figure 1](#f1-ehp0113-000391){ref-type="fig"}). NHANES III, conducted from 1988 through 1994 by the [@b30-ehp0113-000391], was designed as a nationally representative survey. However, the environmental component, known as the callback cohort (\~ 1,000 adults who agreed that additional blood and urine samples could be taken), was not. Although each demographic group had some representation in the call-back cohort, no rigorous sample design and no sample weights were used in analyzing the resulting data. Furthermore, for this study, we calculated the total sample size (\~ 400) to assure that we could estimate the true proportion of the population with measurable BPA and/or NP urinary concentrations within 6.5 percentage points with 99% confidence. It is likely that this sample size was too small to detect significant differences between the various subgroups defined by age, residence, and sex. Even though our population does not represent the composition of the general U.S. population and the sample size is relatively small, our reported values are from a diverse adult U.S. population, a larger and broader population base than those in previous studies ([@b1-ehp0113-000391]; [@b26-ehp0113-000391]; [@b31-ehp0113-000391]; [@b44-ehp0113-000391]).

The median concentrations of BPA in the NHANES III samples analyzed were similar to the concentrations found in a group of 48 Japanese adults ([@b31-ehp0113-000391]), but the GM concentration of BPA was about seven times lower than in a group of 73 adult Koreans ([@b44-ehp0113-000391]). These data suggest that differences in the exposure to BPA may exist geographically. However, because of the relatively small sample size of these studies, the data should be interpreted cautiously. The range of NP concentrations in the NHANES III samples compared well with previous data ([@b15-ehp0113-000391]; [@b17-ehp0113-000391]).

The relatively low NP concentrations and lower frequency of detection compared with that of BPA may result, at least in part, from alternative metabolic pathways. Orally administered BPA is rapidly metabolized to its monoglucuronide in rats ([@b33-ehp0113-000391]) and humans ([@b40-ehp0113-000391]) and excreted in the urine. In six adult volunteers administered orally with D~16~-BPA (5 mg), D~16~-BPA was rapidly absorbed from the gastrointestinal tract. The urinary excretion and elimination from blood of D~16~-BPA glucuronide were very similar, with terminal half-lives of 5.4 hr and 5.3 hr, respectively. Furthermore, the applied dose of D~16~-BPA was completely recovered in urine as D~16~-BPA glucuronide approximately 24 hr after administration ([@b40-ehp0113-000391]). In turn, after oral application of ^13^C~6~-NP (5 mg) to a human volunteer, [@b28-ehp0113-000391] showed that only 10% of the dose was excreted in the urine as NP within 8 hr and suggested the occurrence of additional metabolites, which could not be identified with their method. Other studies have demonstrated that NP undergoes metabolism in fish ([@b3-ehp0113-000391]; [@b37-ehp0113-000391], [@b38-ehp0113-000391]) and rats ([@b4-ehp0113-000391]; [@b7-ehp0113-000391]; [@b46-ehp0113-000391]) resulting both in side chain- and ring-hydroxylated NP metabolites. In Wistar rats, a major percentage (\~ 75%) of ring-2,6--^3^H--nNP, administered by gavage, or oral administered ^14^C~6~-nNP was excreted in urine in the form of free, glucuronidated, or sulfated oxidative metabolites, primarily C1 and C3 side-chain oxidative metabolites resulting from ω- or β-oxidation of the NP C9 side chain ([@b46-ehp0113-000391]). Several metabolites were characterized by negative ion electrospray-ion trap MS, namely, *p*-hydroxybenzoic acid, 3-(4-hydroxyphenyl)-2-propionic acid, 3-(4-hydroxyphenyl)-2-propenoic acid, and a ring-hydroxylated 3-(4-hydroxyphenyl)-2-propionic acid. No nNP was detected in urine ([@b46-ehp0113-000391]). In rainbow trout, after oral ingestion of ring-2,6--^3^H--nNP, the major urinary metabolites were tentatively identified as oxidative metabolites ([@b38-ehp0113-000391]). In another study, the excretion in urine of unchanged ^14^C~6~-nNP in CD rats after oral administration of the radiolabeled NP was estimated to be \< 5% of the dose ([@b7-ehp0113-000391]). In Sprague-Dawley rats, after oral administration of NP, containing 95% of branched side-chain NP isomers, considerable amounts of aromatic ring hydroxylated glucuronides were detected in serum and liver based on MS fragmentation properties ([@b4-ehp0113-000391]; [@b7-ehp0113-000391]; [@b46-ehp0113-000391]).

If the oxidative metabolism of NP also prevails in humans, the use of NP as the sole urinary biomarker for comparing relative exposures of NP to other environmental phenols (e.g., BPA) in a given study may be misleading because the metabolism of NP is more complex and results in more metabolites, thus decreasing the relative amounts of NP in the urine. Although ingested BPA is completely recovered in urine as BPA glucuronide within approximately 24 hr after exposure ([@b40-ehp0113-000391]), only 10% of the ingested NP is excreted in the urine as NP or conjugated NP (e.g., glucuronide) ([@b28-ehp0113-000391]). Furthermore, given the method of manufacturing NP, little of the linear chain NP (i.e., nNP) is produced ([@b5-ehp0113-000391]). Therefore, nNP, the compound we actually measured in this study, represented only a small percentage of the NP present in the NP commercial mixtures. Unfortunately, the lack of authentic standards and isotope-labeled standards of branched NPs precluded their quantification ([@b20-ehp0113-000391]). Studies are ongoing in our laboratory to determine whether the NP oxidative metabolites tentatively identified in animal studies, including the metabolites of branched alkyl chain NPs, can be used to assess exposure to NP in humans.

In summary, despite the sample population's relatively small size and its nonrepresentativeness of the U.S. population (although we used sample weights to improve the extent to which the results represent the U.S. population), this study provides the first reference range of human internal dose levels of BPA and NP. The higher frequency of detection of BPA than of NP in urine suggests that human exposure to BPA is more prevalent. However, because an oxidative metabolism pathway for NP may be relevant in humans and nNP---the NP isomer measured in this study---represents a small percentage of the NP used in commercial mixtures, exposure to NP may be underestimated. Additional research to establish the relevance of oxidative metabolism of NP in humans and to identify the urinary metabolites of NP commercial mixtures is warranted. Furthermore, the frequent human exposure to these compounds highlights the need for future studies to measure BPA and NP in a nationally representative sample of the U.S. population.

![Ninety-fifth percentile concentration (in μg/L and μg/g creatinine) of NP in a human reference population of 371 adults. The frequency of detection of NP was 51%, and the median concentration was \< 0.1 μg/L. For each demographic subgroup, the frequency of detection was 53% (\< 50 years of age), 45% (≥50 years of age), 51% (rural resident), 51% (urban resident), 55% (male), and 48% (female). The median concentrations of NP were \< 0.1 μg/L, except for males (0.17 μg/L), urban residents (0.11 μg/L), and those \< 50 years of age (0.11 μg/L).](ehp0113-000391f1){#f1-ehp0113-000391}

###### 

GM and selected percentiles of BPA concentrations \[μg/L (μg/g creatinine)\] in urine.

                                     Percentile                                                                            
  -------------------- ------------- --------------- ------------- ------------- ------------- ------------- ------------- ----------
  Total                1.33 (1.36)   0.22 (0.23)     0.58 (0.70)   1.28 (1.32)   2.46 (2.58)   4.10 (3.88)   5.18 (7.95)   394 (95)
  Age group (years)                                                                                                        
  \< 50                1.43 (1.34)   0.44 (0.44)     0.84 (0.74)   1.87 (1.53)   3.13 (2.34)   5.15 (3.77)   7.51 (6.64)   317 (95)
  ≥50                  0.99 (1.44)   0.18 (0.15)     0.51 (0.65)   1.23 (1.29)   2.32 (2.60)   4.00 (3.88)   4.83 (7.95)   77 (94)
  Place of residence                                                                                                       
  Rural                1.44 (1.60)   0.38 (0.36)     0.69 (0.73)   1.28 (1.37)   2.35 (2.58)   3.79 (3.83)   4.76 (9.06)   153 (99)
  Urban                1.27 (1.23)   0.18 (\< LOD)   0.41 (0.53)   1.27 (1.20)   2.58 (2.60)   4.42 (3.88)   6.26 (7.95)   241 (92)
  Sex                                                                                                                      
  Male                 1.63 (1.35)   0.40 (0.15)     0.71 (0.57)   1.30 (1.20)   2.36 (1.91)   4.42 (3.05)   8.02 (7.95)   184 (96)
  Female               1.12 (1.35)   0.17 (0.36)     0.49 (0.72)   1.27 (1.77)   2.46 (2.95)   3.68 (4.49)   4.83 (9.06)   210 (94)

LOD is 0.1 μg/L.

Number of subjects (percentage of detection).

###### 

Multivariate model[*^a^*](#tfn3-ehp0113-000391){ref-type="table-fn"} considering the relation of measured BPA[*^b^*](#tfn4-ehp0113-000391){ref-type="table-fn"} to independent predictor variables.

  Independent variable     Specification   No.   GM[*^c^*](#tfn5-ehp0113-000391){ref-type="table-fn"}       *p*-Value
  ------------------------ --------------- ----- ---------------------------------------------------------- -----------
  Residence                Rural           153   1.56                                                       0.0014
                           Urban           241   1.21                                                       
  Creatinine               Continuous      394   0.039[*^d^*](#tfn6-ehp0113-000391){ref-type="table-fn"}    \< 0.0001
  Residence × creatinine   Rural           153   −0.015[*^d^*](#tfn6-ehp0113-000391){ref-type="table-fn"}   0.0249
                           Urban           241                                                              

Each variable was adjusted for the others in the model; *r*^2^ for the model is 0.26.

The dependent variable is log~10~(BPA) for model calculations (μg/L).

Model-calculated GM.

Values shown are β\[i.e., slope from the multivariate analysis of the regression of log~10~(BPA) versus the continuous independent variable\].
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